The role of antiandrogen monotherapy in the treatment of prostate cancer

@article{Anderson2003TheRO,
  title={The role of antiandrogen monotherapy in the treatment of prostate cancer},
  author={J. Anderson},
  journal={BJU International},
  year={2003},
  volume={91}
}
  • J. Anderson
  • Published 2003
  • Medicine
  • BJU International
  • The mainstay of hormonal therapy in prostate cancer has been medical or surgical castration, both of which are associated with loss of libido and impotence, and may not always be acceptable to the patient. Antiandrogen monotherapy is an alternative treatment option to castration. There are two types of antiandrogen, i.e. steroidal (cyproterone acetate, CPA), and nonsteroidal (bicalutamide, flutamide and nilutamide). Data comparing survival outcome with CPA and castration are limited and… CONTINUE READING
    108 Citations
    Antiandrogens in the treatment of prostate cancer.
    • 78
    Antiandrogen treatments in locally advanced prostate cancer: are they all the same?
    • D. Gillatt
    • Medicine
    • Journal of Cancer Research and Clinical Oncology
    • 2006
    • 52
    Hormonal therapy and chemotherapy for advanced prostate cancer
    • 3
    • PDF

    References

    SHOWING 1-10 OF 45 REFERENCES
    Nilutamide: An Antiandrogen for the Treatment of Prostate Cancer
    • 43
    Antiandrogens: a summary review of pharmacodynamic properties and tolerability in prostate cancer therapy.
    • 34
    Bicalutamide monotherapy versus flutamide plus goserelin in prostate cancer patients: results of an Italian Prostate Cancer Project study.
    • 136
    Double-blind, randomized study of primary hormonal treatment of stage D2 prostate carcinoma: flutamide versus diethylstilbestrol.
    • A. Chang, B. Yeap, +8 authors D. Trump
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1996
    • 113